Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | First-Line Chronic Lymphocytic Leukemia | US/EU | 2017
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
Renal Cell Carcinoma | Access and Reimbursement | Implications of Physician Dispensing of Oral Oncolytics for Renal Cell Carcinoma | US | 2017
The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state…
Schizophrenia | Access and Reimbursement | Depot Antipsychotic Use | US | 2017
Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a compelling advantage because of their less…
Acute Myeloid Leukemia | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
